A pharmacodynamic study with ticagrelor in African American patients

Exclusion Criteria

• - Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve) or dual antiplatelet treatment (e.g., clopidogrel, prasugrel, ASA dose other than 75 to 100 mg daily) during study period
• - Patients who had ACS or stent placed within 12 months of screening Patients with a history of moderate or severe hepatic impairment
• - Current smokers, including the use of tobacco containing products in the past 1 month of randomization Patients required dialysis